Royalty Pharma and Pablo and Almudena Legorreta Support Development of Antibody Based Covid-19 Therapy at The Rockefeller University

Download PDF

NEW YORK, NY, December 17, 2020 Royalty Pharma (Nasdaq: RPRX) and The Rockefeller University announced generous gifts totaling $5,760,000 from Royalty Pharma and Pablo and Almudena Legorreta. Half of the gift will be donated by Royalty Pharma and the other half by Pablo and Almudena Legorreta personally. These gifts will support late-stage research and clinical development of a new antibody-based therapy designed to fight SARS-CoV-2, the virus that causes COVID-19. Mr. Legorreta is founder and CEO of Royalty Pharma, a leading funder of innovation across the biopharmaceutical industry, as well as a Rockefeller University Trustee.

This new funding will advance the pioneering work of immunologist Michel C. Nussenzweig, M.D., Ph.D., and his laboratory team. Dr. Nussenzweig is the Zanvil A. Cohn and Ralph M. Steinman Professor at Rockefeller and an Investigator with the Howard Hughes Medical Institute. He is also a senior physician at The Rockefeller University Hospital, a unique research facility on the Rockefeller campus, where an initial Phase I trial of the new investigational antibody therapy is expected to begin next month. Devoted entirely to patient-based research, Rockefeller’s Hospital is ideally suited to serve as the site of this first-in-human clinical trial.

The focus will be a pair of broadly neutralizing antibodies that Dr. Nussenzweig and his colleagues isolated last spring from the blood of people who had recovered from SARS-CoV-2 infection. Using molecular technologies they developed, they were able to identify and clone the genes that produce the most powerful anti-SARS-CoV-2 antibodies. Over the past months, the scientists optimized these antibodies, making them longer lasting. The antibody combination is designed to bind to and disable two distinct sections of the virus’s outer spike protein, thereby blocking the microbe’s ability to infect human cells.

When the COVID pandemic struck in early 2020, the Nussenzweig lab was ideally positioned to launch this clinical development effort, building directly on their experience designing antibody-based interventions for HIV, Zika, and other viral pathogens. In January 2020, the lab’s portfolio of anti-HIV antibodies was licensed to Gilead Sciences, which is exploring their use for therapy, prevention and a potential cure for HIV/AIDS.

The lab’s new anti-SARS-CoV-2 antibodies have been studied in partnership with scientists worldwide, including Rockefeller virologists Paul Bieniasz, Theodora Hatziioannou, and Charles Rice, a recipient of the 2020 Nobel Prize in medicine, as well as structural biologist Pamela Bjorkman of Caltech, and many others.

Rockefeller University President Richard P. Lifton notes, “Antibody treatments will be a crucial part of our medical armamentarium against COVID-19 going forward, even with the availability of new vaccines. Antibodies can provide acute or chronic protection for individuals whose immune systems cannot adequately respond to a vaccine, and also serve as an effective therapeutic for people in the early stages of infection.

“We are tremendously grateful to Pablo and Almudena Legorreta and the Royalty Pharma family for their transformative gift at this key moment,” continued Dr. Lifton. “Pablo and his Royalty Pharma colleagues have been extraordinarily helpful partners, providing expertise and wise counsel, as well as critical funding, throughout the SARS-CoV-2 antibody development process.”

Pablo Legorreta said, “My wife, Almudena, and I are tremendously encouraged by the progress of the Nussenzweig lab’s research and pleased to be able to help them move their potentially life-saving antibody therapy toward the clinic. We have long admired Michel’s work at the frontiers of immunology and want to support his team’s efforts to address the current health crisis. We are also delighted to be a part of the Rockefeller University community and very proud of the university’s many enduring contributions to biomedical discovery and disease-focused innovation. As COVID continues to strain communities, Royalty Pharma is committed to supporting academic research centers and teaching hospitals who are on the frontlines of fighting this pandemic.”

About Royalty Pharma Plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly—directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products,
including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’s Promacta, and Vertex’s Kalydeco, Symdeko, Orkambi and Trikafta, and four development-stage product candidates. For more information, visit

About The Rockefeller University

Rockefeller University is one of the world’s leading biomedical research universities and is dedicated to conducting innovative, high-quality research to improve the understanding of life for the benefit of humanity. Rockefeller’s 70 laboratories conduct research in immunology, biochemistry, genomics, neuroscience, and many other areas, and a community of more than 2,000 faculty, students, postdocs, technicians, clinicians, and administrative personnel work on the university’s 16-acre Manhattan campus. Rockefeller’s unique approach to science has led to some of the world’s most revolutionary and transformative contributions to biology and medicine. During Rockefeller’s 119-year history, 26 Rockefeller scientists have won Nobel Prizes, 24 have received Albert Lasker Medical Research Awards, and 20 have garnered the National Medal of Science, the highest science award given by the United States.

Royalty Pharma plc’s Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Royalty Pharma’s own internal estimates and research. While Royalty Pharma believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source. For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at

Royalty Pharma Investor Relations and Communications

+1 (212) 883-2295

The Rockefeller University Media Relations

+ 1 (212)-327-7913

Stay up to date

Subscribe to Royalty Pharma news and alerts